The Claim
Chronic inhibition of the myostatin–activin pathway with bimagrumab in healthy older adults does not induce pathological cardiac hypertrophy, despite inducing skeletal muscle hypertrophy.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In healthy older adults, a drug called bimagrumab increases skeletal muscle mass but does not cause harmful enlargement of the heart.
See the scientific wording
Chronic inhibition of the myostatin–activin pathway with bimagrumab does not induce pathological cardiac hypertrophy in healthy older adults, despite causing skeletal muscle hypertrophy, suggesting cardiac tissue responds differently than skeletal muscle to this intervention.
Blocking a specific signal that normally limits muscle growth makes skeletal muscles bigger, but the heart does not grow because it does not respond to this signal in the same way, and the muscle increase is too small to force the heart to adapt.
What the research says
1 studyThis drug makes muscles bigger in older people, but their hearts stayed the same size and worked just as well—so the heart doesn’t get hurt or grow abnormally like the muscles do.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.